Royal Bank of Canada
TCRR

Royal Bank of Canada’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Royal Bank of Canada’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-85
Closed – – 7947
2023
Q1 		$0 Hold
85
– – ﹤0.01% 7717
2022
Q4 		$0 Hold
85
– – ﹤0.01% 8032
2022
Q3 		$0 Sell
85
-58
-41% -$168 ﹤0.01% 8115
2022
Q2 		$0 Sell
143
-1,816
-93% -$4.48K ﹤0.01% 7984
2022
Q1 		$5K Sell
1,959
-4,666
-70% -$14.7K ﹤0.01% 7286
2021
Q4 		$31K Buy
6,625
+3,523
+114% +$22K ﹤0.01% 6614
2021
Q3 		$27K Buy
3,102
+849
+38% +$12K ﹤0.01% 6528
2021
Q2 		$36K Sell
2,253
-30
-1% -$606 ﹤0.01% 6250
2021
Q1 		$51K Buy
2,283
+1,576
+223% +$43K ﹤0.01% 5871
2020
Q4 		$22K Buy
707
+676
+2,181% +$17.1K ﹤0.01% 6025
2020
Q3 		$1K Buy
31
+7
+29% +$123 ﹤0.01% 6521
2020
Q2 		$0 Sell
24
-252
-91% -$2.91K ﹤0.01% 7029
2020
Q1 		$2K Sell
276
-798
-74% -$9.77K ﹤0.01% 6358
2019
Q4 		$15K Buy
1,074
+1,018
+1,818% +$15.7K ﹤0.01% 6001
2019
Q3 		$1K Buy
+56
New +$872 ﹤0.01% 6564

Royal Bank of Canada's TCRR Position: Q2 2023 in Review

Royal Bank of Canada sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 85 shares.

Royal Bank of Canada first reported a position in TCRR in Q3 2019 and held it in 15 quarters. The position peaked at $51K in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Royal Bank of Canada reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 85 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023.
  • Royal Bank of Canada first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 15 quarters.
  • Royal Bank of Canada's TCR2 Therapeutics Inc. Common Stock position peaked at $51K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.